过去 90 天内没有内部人买入。最近一笔由 UNITED BIOMEDICAL INC 披露于 2022年6月21日。
Vaxxinity, Inc.：高管交易动态
Vaxxinity, Inc.属于医疗与制药行业。其高管的申报经由SEC (Form 4)发布。十二个月来，Vaxxinity, Inc.的高管没有新的申报，最新记录停留在2023年9月8日。
我们关于Vaxxinity, Inc.的记录可追溯至2021年，累计有15笔买入和34笔卖出。
如需在同一行业内比较，可查看Dynavox Group AB和Vetoquinol SA的高管买入记录。以上数据均来自SEC (Form 4)发布的申报，描述的是过去的情况，不代表未来股价走势，也不构成投资建议。
内部人买入以来
- +17.0%入场价 US$1.94 · T+365 收盘 US$2.27
- -12.7%入场价 US$2.28 · T+365 收盘 US$1.99
- -12.7%入场价 US$2.28 · T+365 收盘 US$1.99
入场价为披露次日收盘价，即读者可操作的第一个价格。价格以上市货币计。过往涨跌不代表未来表现。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2023财年截至 2023年12月 · cache
- 4,786 股@ US$1.78720.0% 占其流量股票SEC:0001062993-23-017880:5
- 507 股@ US$1.8823股票SEC:0001062993-23-017880:2
- 892 股@ US$1.8823股票SEC:0001062993-23-017880:3
- 2,189 股@ US$1.8823股票SEC:0001062993-23-017880:4
- 5,308 股@ US$1.88230.0% 占其流量股票SEC:0001062993-23-017880:1
- 1,939 股@ US$1.7872股票SEC:0001062993-23-017880:7
- 3,413 股@ US$1.7872股票SEC:0001062993-23-017880:8
- 5,911 股@ US$1.670.0% 占其流量股票SEC:0001062993-23-017880:10
- 2,395 股@ US$1.67股票SEC:0001062993-23-017880:12
- 1,251 股@ US$1.88234.1% 占其流量股票SEC:0001062993-23-017880:0
- 46,500 股@ US$1.210.0% 占其流量股票SEC:0001437749-23-012008:1
- 429,037 股@ €0.5163.0% 占其流量股票SEC:0001437749-23-012008:0
- 405,217 股@ US$3.3514股票SEC:0001062993-23-001392:1
- 95,475 股@ US$3.351455.5% 占其流量股票SEC:0001062993-23-001392:0
- 11,121 股@ US$2.56820.0% 占其流量股票SEC:0001062993-22-023345:3
- 270,964 股@ US$2.9717股票SEC:0001062993-22-023345:1
- 2,620 股@ US$2.5682股票SEC:0001062993-22-023345:2
- 63,843 股@ US$2.971734.3% 占其流量股票SEC:0001062993-22-023345:0
- 2,234 股@ US$2.4029股票SEC:0001062993-22-019372:1
- 3,934 股@ US$2.4029股票SEC:0001062993-22-019372:2
- 25,243 股@ US$2.40290.0% 占其流量股票SEC:0001062993-22-019372:3
- 5,947 股@ US$2.402926.8% 占其流量股票SEC:0001062993-22-019372:0
- 20,000 股@ US$0.000.0% 占其流量股票SEC:0001437749-22-021457:1
- 26,005 股@ US$0.000.0% 占其流量股票SEC:0001437749-22-021457:2
- 2,640 股@ US$0.00020.0% 占其流量股票SEC:0001437749-22-021457:3
91 条申报中的 25 条
About Vaxxinity, Inc.
Vaxxinity, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker VAXX. The company is headquartered in Dallas, Texas, United States, with its public business address shown at 2622 Commerce St., Dallas, TX 75226. Vaxxinity describes itself as a developer of next-generation immunotherapeutic vaccines and antibody-inducing medicines aimed at chronic diseases rather than only traditional infectious-disease vaccination. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai))
Historically, Vaxxinity emerged from the United Biomedical ecosystem and was built around the idea of commercializing a synthetic-peptide vaccine approach at scale. Management positions the company as a platform biotech designed to create medicines that harness the immune system to generate antibodies, with an emphasis on affordability, stability, and manufacturability. The company’s official science materials state that its AIM (Active Immunotherapy Medicine) platform uses synthetic peptides to selectively activate the immune system and that the platform has been validated through animal-health use and multiple human clinical trials. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai))
展开全文收起
From an operating perspective, Vaxxinity is primarily a clinical-stage company. It does not rely on a broad commercial portfolio of marketed products; instead, value creation is tied to a pipeline of investigational assets. Its main programs include UB-311 for Alzheimer’s disease, UB-312 targeting aggregated alpha-synuclein for Parkinson’s disease and related synucleinopathies, VXX-401 for lowering LDL cholesterol via PCSK9 biology, and a COVID-related program built around a multitope immune response. This gives Vaxxinity exposure to several large therapeutic markets, but also makes the investment case highly dependent on clinical outcomes and regulatory progress. ([vaxxinity.com](https://vaxxinity.com/our-pipeline/?utm_source=openai))
In competitive terms, Vaxxinity differentiates itself through a synthetic peptide platform and a value proposition centered on cold-chain practicality and scalable manufacturing. The company emphasizes that some of its candidates can be stored and shipped at conventional 2–8°C temperatures, which could be advantageous if later-stage development succeeds and commercialization becomes possible. That said, it competes in highly crowded and scientifically demanding fields, including neurology, cardiovascular disease, and infectious disease, where large-cap pharma and well-funded biotech peers have materially greater resources. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai))
Geographically, Vaxxinity is a U.S. company with an international development footprint, but its corporate identity, listing venue, and headquarters are clearly American. For investors in France, Belgium, and Switzerland, VAXX should be viewed as a NASDAQ-listed biotech with asymmetric upside potential but substantial execution risk. Recent company messaging continues to highlight pipeline advancement, especially in Alzheimer’s and Parkinson’s-related programs, underscoring that the near-term equity story is still driven by research progress rather than product revenue. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai))
同行业近期入选信号
我们的模型当前为推荐列表排序的买入。
全部推荐
